From the Wires
Pyng Medical Corp. Reports First Quarter Fiscal 2013 Results
By: Marketwired .
Feb. 26, 2013 07:56 PM
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/27/13 -- Pyng Medical Corp. (TSX VENTURE:PYT) today announced financial and operating results for the three months ended December 31, 2012. All amounts are in Canadian dollars unless stated otherwise.
The Company reported total sales of $1,043,308 for the three months ended December 31, 2012, down 21% compared with $1,327,190 for the same quarter last year. The decreased revenue is primarily attributed to ongoing declines in purchases from the USA military, likely due to USA federal budget concerns. Gross margin decreased to $523,942, from $818,491 reported a year ago. Gross margin as a percentage of revenue decreased from 62% to 50%, and is attributed to a combination of lower revenues, higher landed costs for raw materials, costs related to outsourcing the Richmond, BC manufacturing facility and associated staff termination expenses. Total operating expenses went up 3% to $732,888 from $708,195 for the first quarter of last year as a result of higher sales and marketing, product development and interest expenses incurred.
The Company also reported a net loss of $260,043 for this quarter, equal to loss of $0.02 per share, compared to a net income of $105,641 or earning $0.01 per share one year earlier. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations were negative $96,551, a decrease of $363,951 from $267,400 reported for the first quarter of fiscal 2012.
As at December 31, 2012, the Company had a cash balance of $206,514, a decrease of $77,083 compared with the balance of $283,597 as at September 30, 2012. The working capital deficiency increased to $402,486 from $196,463 as at September 30, 2012, due to lower margins, higher marketing and sales expenses, and FASTx re-launch costs.
The Company continues to pursue debt and/or equity financing to help fund its working capital needs. Management hopes to secure the necessary financing through the combination of new credit facilities and issuance of new equity or convertible debt instruments. There can be no assurance that these initiatives will be successful.
Full audited financial results for fiscal year ended September 30, 2012 are available on SEDAR at www.sedar.com.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week